Abstract
Graves’ disease is a multisystem disorder and the most common autoimmune disease. Fifty percent of patients with Graves’ disease shows orbital involvement, called Graves’ orbitopathy. Although Graves’ orbitopathy is a self-limiting disease, spontaneous improvement can only be awaited in its milder forms.
You have full access to this open access chapter, Download chapter PDF
Similar content being viewed by others
Keywords
- Graves’ disease
- Graves’ thyroid disease
- Graves’ orbitopathy
- Incidence
- Prevalence
- Risk factors
- Natural course
-
Graves’ orbitopathy is a common autoimmune disease that affects women 5–6 times more than men.
-
The natural course of Graves’ orbitopathy is characterized by a phase of increasing severity, a plateau phase and a phase of decreasing severity.
-
Graves’ orbitopathy starts with an increase of extraocular muscle volume, which is usually accompanied by signs of inflammation.
-
Smoking, old age, high antibody levels and male gender are the most important risk factors to develop severe Graves’ orbitopathy. Thus, women more often have GO than men, but when men have GO, they mostly have a more severe form.
Incidence, Nomenclature, History
With an estimated incidence of 45 (36.8 females, 8.3 males) per 100,000 persons per year, Graves’ disease (GD) is the most common autoimmune disease [1]. GD (or: Basedow’s disease) serves as an umbrella term for Graves’ thyroid disease, Graves’ eye/orbit disease, pretibial myxedema, and acropachy. These subentities can occur together or separately.
Graves’ thyroid disease (GTD) is the most frequent of them. Although the cause is still unknown, the body produces TSH-receptor-binding immunoglobulins (TBII) which either stimulate, suppress or do not influence thyroid function. As a result, circa 85% of patients with GTD are hyperthyroid, 5–10% are hypothyroid, and the remainder are euthyroid.
Depending upon the criteria used, approximately 50% of GD patients have Graves’ eye/orbit disease, called Graves’ Orbitopathy or Ophthalmopathy in most European countries (GO), Thyroid Associated Orbitopathy (TAO) in the UK, and GO or Thyroid Eye Disease (TED) in the United States of America.
Pretibial myxedema, that is reddish, thickened areas on the lower legs, often associated with pruritis, and acropachy, i.e., soft-tissue swelling of the hands and clubbing of the fingers due to periostitis of the metacarpal bones, is rare. When present together with GO, the symptoms are usually more severe [2].
The oldest descriptions of what we now call GD, among which a combination of goiter, tachycardia and exophthalmos, the so-called Merseburger trias, are from the Welshman Caleb Hillier Parry (Fig. 14.1, 1786, published in 1825), the Dubliner Robert James Graves (Fig. 14.2, 1835) and the German Carl Adolph von Basedow (Fig. 14.3, 1840).
Temporal Relationship Go with GTD, Risk Factors
The majority of patients develop GTD and GO within a time span of 12 months; in a minority of patients, the onset of the eye complaints precedes the thyroid disease, whereas in some more patients, the eye disease starts after the onset of GTD. Approximately, 15% develop GO more than 5 years after the onset of their GTD [3]. Patients may develop GO in the absence of hyperthyroidism. This is called euthyroid GO.
GO is 5–6 times more frequent in females. Although GO may start at any age (from 0 to 100), it is most frequent in women between 30 and 60 years of age. Men often develop GO at older age and suffer from more severe forms. GO at childhood is extremely rare; soft tissue involvement and proptosis are the more frequent signs in children with GO [4].
Risk factors to develop GO are as follows
-
1.
Smoking [5]
-
2.
Female gender
-
3.
Radioactive iodine treatment [6]
-
4.
Iatrogenic hypothyroidism [6]
Risk factors to develop severe GO are as follows
Natural Course
As Rundle described in 1957 [10], untreated GO has a biphasic course. It starts with a period of increasing severity, then reaches a plateau phase and subsequently a phase of spontaneous improvement (Fig. 14.4), although a complete disappearance of symptoms and signs is mostly not to be expected.
The initial phase is called the active phase and is usually accompanied by signs of inflammation, such as red, swollen eyelids, pain and worsening (Chap. 15). During the inactive phase, signs of inflammation disappear; exophthalmos, eyelid retraction and motility impairment (might) remain. The duration of the several phases varies considerably. A total length of 3–5 years is no exception.
Exophthalmos in GO is the result of two pathological processes in the orbit: an increase of orbital contents by neo-adipogenesis and an increase of muscle volume (Fig. 14.5). Recently, we have studied the course of mild GO in terms of volume changes. We, therefore, had adopted and validated a CT-based method (Mimics, Materialise) for the calculation of orbital soft tissue volumes [11]. We found that an increase in muscle volume is an early phenomenon and coincides with inflammatory changes. After about 1 year, muscle volume deceases slightly (with 1 cm3), but fat volume starts to increase over the next 4 years (with almost 2 cm3) and then stabilizes. Interestingly, this fat volume increase does not seem to be related to inflammatory changes [12].
Differences in the duration and severity of these two processes might explain the different presentations of GO. Of interest is also that smoking is associated with both muscle volume increase and inflammatory changes [13].
A strong relationship has been found between smoking and the severity of GO (Fig. 14.6) [5].
In 95 newly diagnosed patients with GO, we found that in 25% of them, the muscle and fat volumes were within the limits of normalcy; 61% of the patients only had an increase of muscle volume, 5% only an increase in fat volume and 9% demonstrated an increase in both muscle and fat volume [14].
Auto-antibodies, such as TBII, correlate with the severity and activity of GO [15, 16] and have prognostic significance for the course of GO [16]. Iatrogenic hypothyroidism and treatment with radio-active iodine may worsen the orbitopathy [17, 18].
Once GO has burnt out, it is unlikely to flare up again. However, we have seen recurrences as late as 7 years after the first episode [19].
During pregnancy, TBII serum levels decrease and the orbitopathy declines. However, post-partum antibody titers often increase to levels that exceed pre-pregnancy values and can cause a recurrence of GO and a clinical relapse of disease activity [20].
References
Furszyfer J, Kurland LT, McConahey WM, Elveback LR. Graves’ disease in Olmsted County, Minnesota, 1935 through 1967. Mayo Clin Proc. 1970;45:636–44.
Fatourechi V, Bartley GB, Eghbali-Fatourechi GZ, Powell GC, Ahmed DD, Garrity JA. Graves’ dermopathy and acropachy are markers of severe Graves’ ophthalmopathy. Thyroid. 2003;13:1141–4.
Wiersinga WM, Smit T, Van Der Gaag R, Koornneef L. Temporal relationship between the onset of Graves’ ophthalmopathy and onset of thyroidal Graves’ disease. J Endocrinol Investig. 1988;11:615–9.
Chan W, Wong GH, Fan SD, Cheng AC, Lam DS, Ng IS. Ophthalmopathy in childhood Graves’ disease. Br J Ophthalmol. 2002;86:740–2.
Prummel MF, Wiersinga WM. Smoking and the risk of Graves’ orbitopathy. JAMA. 1993;269:479–82.
Li HX, Xiang N, Hu WK, Jiao XL. Relation between therapy options for Graves’ disease and the course of Graves’ ophthalmopathy: a systematic review and meta-analysis. J Endocrinol Investig. 2016;39:1225–33.
Kalmann R, Mourits MP. Diabetes mellitus: a risk factor in patients with Graves’ orbitopathy. Br J Ophthalmol. 1999;83:463–5.
Eckstein A, Esser J, Mann K, Schott M. Clinical value of TSH receptor antibodies measurement in patients with Graves’ orbitopathy. Pediatr Endocrinol Rev. 2010;7(Suppl 2):198–203.
Eckstein AK, Plicht M, Lax H, Neuhauser M, Mann K, Lederbogen S, Heckmann C, Esser J, Morgenthaler NG. Thyrotropin receptor autoantibodies are independent risk factors for Graves’ ophthalmopathy and help to predict severity and outcome of the disease. J Clin Endocrinol Metab. 2006;91:3464–70.
Rundle FF. Management of exophthalmos and related ocular changes in Graves’ disease. Metabolism. 1957;6:36–48.
Regensburg NI, Kok PH, Zonneveld FW, Baldeschi BL, Saeed P, Wiersinga WM, Mourits MP. A new and validated CT-based method for the calculation of orbital soft tissue volumes. Invest Ophthalmol Vis Sci. 2008;49:1758–62.
Potgieser PW, De Win MML, Wiersinga WM, Mourits MP. Natural course of mild Graves’ orbitopathy: increase of orbital fat but decrease of muscle volume with increased fatty degeneration during a 4-year follow-up. Ophthalmic Plastic Reconstr Surg. 2019;35:456–60.
Regensburg NI, Wiersinga WM, Berendschot TTJM, Saeed P, Mourits MP. Effect of smoking on orbital fat and muscle volume in Graves’ orbitopathy. Thyroid. 2011;21:177–81.
Regensburg NI, Wiersinga WM, Berendschot TTJM, Potgieser P, Mourits MP. Do subtypes of Graves’ orbitopathy exist? Ophthalmology. 2011;118:191–6.
Morris JC, Hay ID, Nelson RE, Jiang NS. Clinical utility of thyrotropin receptor antibody assays: comparison of radioreceptor and bioassay methods. Mayo Clin Proc. 1988;63:707–12.
Gerding MN, Van Der Meer JWC, Broenink M, Bakker O, Wiersinga WM, Prummel MF. Association of thyrotropin receptor antibodies with the clinical features of Graves’ ophthalmopathy. Clin Endocrinol. 2000;52:267–71.
Prummel MF, Wiersinga WM, Mourits MP, Koornneef L, Berghout A, Van Der Gaag R. Effect of abnormal thyroid function on the severity of Graves’ ophthalmopathy. Arch Intern Med. 1990;50:1098–101.
Tallstedt L, Lundell G, Torring O, Wallin G, Ljunggren JG, Blomgren H, Tabe A. Occurrence of ophthalmopathy after treatment for Graves’ hyperthyroidism. The Thyroid Study Group. N Engl J Med. 1992;326:1733–8.
Kalmann R, Mourits MP. Late recurrence of unilateral Graves’ orbitopathy on the contralateral side. Am J Ophthalmol. 2002;133:727–9.
Rotondi M, Cappelli C, Pirali B, Pirola I, Magri F, Fonte R, Castellano M, Rosei EA, Chiovato L. The effect of pregnancy on subsequent relapse from Graves’ disease after a successful course of antithyroid drug therapy. J Clin Endocrinol Metab. 2008;93:3985–8.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Open Access This chapter is licensed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.
The images or other third party material in this chapter are included in the chapter's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the chapter's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.
Copyright information
© 2023 The Author(s)
About this chapter
Cite this chapter
Mourits, M.P. (2023). Graves’ Disease: Introduction. In: Gooris, P.J., Mourits, M.P., Bergsma, J. (eds) Surgery in and around the Orbit. Springer, Cham. https://doi.org/10.1007/978-3-031-40697-3_14
Download citation
DOI: https://doi.org/10.1007/978-3-031-40697-3_14
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-40696-6
Online ISBN: 978-3-031-40697-3
eBook Packages: MedicineMedicine (R0)